✦ LIBER ✦

High Response Rate for Treatment With Gemtuzumab Ozogamicin and Cytarabine in Elderly Patients With Acute Myeloid Leukemia and Favorable and Intermediate-I Cytogenetic Risk

✍ Scribed by Sigal Tavor; Einam Rahamim; Nadav Sarid; Uri Rozovski; Lili Gibstein; Freddy Aviv; Ilya Kirsner; Elizabeth Naparstek

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Improved outcome of patients with low- a

✍ Thomas Prebet; Anne Etienne; Raynier Devillier; Emilie Romeo; Aude Charbonnier; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 202 KB 👁 1 views

Gemtuzumab ozogamicin with cytarabine an

✍ G. Specchia; D. Pastore; P. Carluccio; G. Spinosa; M. Giannoccaro; R. Rizzi; A. 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 95 KB

Twice-Daily Fludarabine and Cytarabine C

✍ Elias Jabbour; Guillermo Garcia-Manero; Jorge Cortes; Farhad Ravandi; William Pl 📂 Article 📅 2012 🏛 Elsevier 🌐 English ⚖ 492 KB

Probable veno-occlusive disease after tr

✍ Kevin P. O’Boyle; Ashwin Murigeppa; Dharamvir Jain; Leonard Dauber; Janice P. Du 📂 Article 📅 2003 🏛 Springer US 🌐 English ⚖ 83 KB

Phase 1 trial of gemtuzumab ozogamicin i

✍ Yoshikazu Ito, Atsushi Wakita, Satoru Takada… 📂 Article 📅 2012 🏛 Carden Jennings Publishing 🌐 English ⚖ 232 KB

Dose-intense etoposide–cyclophosphamide

✍ Trifilio, Steven; Zhou, Zheng; Altman, Jessica; Frankfurt, Olga; Pantiru, Mihael 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 786 KB